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A b s t r a c t
Background and aim: The primary cause of long-term failure of bioprosthetic valves is structural valve deterioration due to 
tissue calcification. A novel anti-calcification technology platform was developed that may irreversibly block calcium binding 
sites in bioprosthetic valves. 
Methods: Twenty patients with severe aortic stenosis underwent isolated aortic valve replacement using a bioprosthetic 
valve treated with the novel anti-calcification technology. Mean patient age and body mass index was 73.7 ± 4.8 years and 
30.1 ± 5.8 kg/m2, respectively. Females comprised 65% of the patient population, and 30% of the population was in New 
York Heart Association class III/IV. Other baseline characteristics included hypertension (90%), hyperlipidaemia (75%), diabetes 
(35%), renal failure (25%), pulmonary disease (10%), and myocardial infarction (10%). Patients were followed-up for up to 
one year. Haemodynamic performance was evaluated by echocardiography. All complications were recorded. 
Results: There was one early death on postoperative day five. No other complications were noted up to discharge. Follow-up 
at 3–6 months and at one year were both 100%. At one year, no valve-related mortality, structural valve deterioration, major 
paravalvular leak (> 2+), thromboembolic events, major bleeding, prosthetic valve endocarditis, or reoperation were observed. 
Mean effective orifice area increased from 1.0 ± 0.5 cm2 at baseline to 1.8 ± 0.5 cm2 at one year. Mean gradient decreased 
from 54.8 ± 21.2 mm Hg at baseline to 11.3 ± 3.4 mm Hg at one year. 
Conclusions: This early clinical experience using an aortic bioprosthetic valve treated with a novel anti-calcification tissue 
processing technology demonstrated excellent valve performance, durability, and safety. No valve-related complications were 
noted. Longer-term follow-up is needed to verify these promising results.
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INTRODUCTION
Aortic valve stenosis (AS) is the most common form of valvular 
heart disease in the Western World and accounts for 43% 
of all patients with valvular heart disease [1, 2]. AS leads to 
greater mortality and morbidity compared to all other cardiac 
valve disease. Without treatment, patient survival is limited 
(2–3 years) following the onset of symptoms [3, 4]. Although 
AS prevalence increases with age, a wide range of patients at 
various ages are affected [5]. 
Two main categories of prostheses for aortic valve replace-
ment (AVR) are available: mechanical and bioprosthetic tissue 
valves. In the past, younger patients (< 65 years old) were 
recommended mechanical valves owing to valve durability [6]. 
However, all mechanical valves required anti-coagulation over 
the lifespan of the patient. Anticoagulation treatment might 
lead to severe bleeding complications.
For younger patients, and especially younger female 
patients with a potential of pregnancy in the future, an 
anti-coagulation regimen is not a viable option [7, 8]. 
Bioprostheses have the advantage of requiring limited or no 
anti-coagulation, but the challenge of durability remains an 
area of development [9, 10]. 
The primary cause of long-term valve failure is struc-
tural valve deterioration (SVD), and it is the most common 
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valve-related complication for bioprosthetic valves. The 
underlying root cause of SVD lies in calcium deposition onto 
the bioprosthesis, which leads to cuspal stiffening and often 
pure stenosis. Additionally, the occurrence of acute aortic 
insufficiency has been reported as progressive forms of calcific 
SVD and can result in tears in the leaflet tissue of some types 
of bioprostheses [11]. To prolong durability and to mitigate 
the impact of SVD by inhibiting calcium deposition onto the 
bioprosthesis, anti-calcification treatments for bioprosthetic 
tissue have been developed in the past [12, 13]. However, 
the onset of bioburden and the subsequent SVD still remains 
unresolved, and the average lifetime of a bioprosthesis remains 
in the range of 10–20 years [11, 14, 15]. To prolong the bio-
prosthetic lifespan by preventing calcific SVD, a novel tissue 
processing technology has been developed that may block 
calcium from binding to sites within the tissue. 
This manuscript reports the one-year outcomes of the 
early feasibility cohort in AVR subjects receiving an aortic 
valve treated with the novel tissue process. Endpoints related 
to valve performance, durability, and safety are reported.
METHODS
Patients
Between July 2011 and September of 2011, 20 patients 
with predominant severe aortic stenosis and often with con-
comitant insufficiency underwent conventional AVR using 
a bioprosthetic valve treated with the novel anti-calcification 
technology (Model 11000, Edwards Lifesciences, LLC). This 
prospective, single-centre confirmatory clinical trial (clinical-
trials.gov #NCT01651052) was sponsored by Edwards Life-
sciences, LLC. The study was performed under Jagiellonian 
University Ethics Committee approval and Polish Ministry of 
Health agreement. 
Patients with aortic valve disease requiring a planned 
replacement with or without concomitant coronary bypass 
surgery were enrolled in the study with written consent. 
Patients were excluded if they met any of the following crite-
ria: aortic valve surgery is emergent; left ventricular ejection 
fraction is < 25%; active endocarditis; concomitant valve 
(mitral, tricuspid, or pulmonic) disease; prior concomitant 
valve surgery; recent history of myocardial infarction; previ-
ous study device implant; history of drug abuse; pregnant; 
or part of another study. The primary safety endpoints of this 
study were those identified by the Objective Performance 
Criteria (ISO 5840:2005-Cardiovascular Implants-Cardiac 
Valve Prostheses): valve-related mortality, thromboembolic 
events, valve thrombosis, major bleeding events, major para-
valvular leak (> 2+), endocarditis, SVD, haemolysis, and 
valve-related reoperation. Performance endpoints for this 
included short-term and long-term regurgitation, patient 
New York Heart Association (NYHA) functional class, and 
haemodynamic performance. Haemodynamic performance 
was evaluated by echocardiography as assessed by an inde-
pendent echocardiographic core laboratory (RadCore Labs, 
Torrance, CA). Patients were followed at discharge, 30 days, 
3–6 months, and one year.
Study device
The aortic valve Model 11000 is a trileaflet bioprosthesis 
comprised of bovine pericardium, treated with a novel 
tissue processing technique that provides anti-calcification 
efficacy [16, 17]. This anti-calcification technology builds 
upon the existing tissue treatment, the ThermaFix Process 
(TFX) (Edwards Lifesciences, LLC), which utilises buffered 
glutaraldehyde and formaldehyde-ethanol-Tween 80 solu-
tion (FET) for tissue fixation, sterilisation, and bioburden 
reduction. Additional elements of the novel tissue process-
ing technique include capping, reduction, ethylene oxide 
sterilisation, and glycerolisation. For the purposes of further 
discussion, the novel tissue processing technique will be 
described as the technology platform and referred to as GLX 
[18]. Capping of functional groups such as aldehydes and free 
acids and reducing the remaining Schiff base sites reduces 
the potential sites for binding of calcium, phosphates, and 
immunogenic factors has been reported [19]. The glycerolisa-
tion treatment inhibits oxidation of the tissue, allowing for 
non-liquid storage and preservation of the structural integrity 
of the collagen matrix in the tissue valve. In this study, the 
aortic bioprosthesis size ranges from 21 to 27 mm (21, 23, 
25, and 27 mm).
Operative procedure
The AVR procedure was performed via full or partial ster-
notomy according to previously described techniques [20]. 
After standard aortotomy (hockey-stick shaped), the diseased 
aortic valve was excised and annulus debrided. Very aggres-
sive calcium debridement was performed in all cases. After 
annular dimension was assessed with a valve sizer, the ap-
propriately sized bioprosthesis was selected and implanted 
in a supra-annular position and the aortotomy closed. No 
rinsing of the study valve was needed due to the fact the 
valves were supplied dry.
Statistical analysis
Continuous variables are summarised as mean and standard 
deviation while categorical variables are summarised as the 
number and percentage of patients in each category. For 
statistical comparison of the continuous data, an unpaired 
t-test was performed to compare the means over time. Early 
(≤ 30 postoperative days) and late (> 30 postoperative days) 
complications and safety endpoints were adjudicated by an 
independent Clinical Endpoints Committee. Aggregate data 
were reviewed by an independent Data Safety Monitoring 
Board. 
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RESULTS
Follow-up at discharge, 3–6 months, and at one year were 
100%. The baseline characteristics of the study group are 
presented in Table 1. 
Technical success was achieved in 100% (20/20) of the 
patients. Isolated AVR comprised the majority of the proce-
dures (95%, 19/20) with only one patient undergoing AVR with 
a concomitant coronary artery bypass grafting (1 patient) pro-
cedure. Five (25%) patients underwent AVR via upper hemi-
sternotomy. Mean cross clamp time and cardiopulmonary 
bypass time were 59.6 ± 10.3 min and 100.4 ± 22.3 min, 
respectively (Table 2). 
One early death occurred on post-operative day five 
following respiratory distress and cardiac arrest, which was 
adjudicated as being related to the index procedure. One 
permanent pacemaker was implanted due to the development 
of atrioventricular block III. This patient demonstrated a left 
bundle branch block at baseline. No incidents of valve-related 
mortality, SVD, major paravalvular leak (> 2+), thromboem-
bolic events, major bleeding, prosthetic valve endocarditis, or 
reoperation were observed up to one year. NYHA functional 
class was improved or remained the same in 84.2% (16/19) 
of the patient population, when comparing class change from 
baseline to one year. 
Haemodynamic performance was improved from 
baseline to one year. Mean gradient for all valve sizes 
decreased from 54.8 ± 21.2 mm Hg at baseline to 
11.3 ± 3.4 mm Hg at one year. Significant increases were 
observed for the 21 and 23 mm valves from baseline to one 
year (p < 0.0001 and p < 0.0013, respectively). Mean effec-
tive orifice area for all valve sizes increased 1.0 ± 0.5 cm2 at 
baseline to 1.8 ± 0.5 cm2 at one year. Significant increases 
were observed for the 21-mm and 25-mm valves from base-
line to one year (p < 0.0009 and p < 0.0125, respectively) 
(Table 3). 
DISCUSSION
The treatment for aortic stenosis began over 60 years ago, 
starting with mechanical valves [21]. While mechanical valves 
offered high durability, intense life-long anti-coagulation 
requirements led to the research and development of tissue 
valves [22, 23]. Over the past six decades, a large number 
of prosthetic heart valves have been under intense research 
and development. 
Though valve design enhancements to reduce material 
fatigue (e.g. design changes to apply net zero pressure on 
the leaflet, lowered stent post and base profile to minimise 
protrusion, and development of thinner, more flexible valve 
stents) have been developed, the bioprosthetic tissue source, 
as well as tissue processing technologies, has also undergone 
significant development.
The first generation of bioprostheses consisted of tissue 
valves from porcine, fixed in formalin. In the late 1960s, 
formalin-fixation was replaced by a far more stable glutaral-
dehyde cross-linking technique, which provided anti-immu-
Table 1. Patient baseline characteristics
Parameter Percentage (n) 
or mean ± SD 
(min–max)
Age [years] 73.7 ± 4.8 (63.0–82.0)
Gender/sex: female 13 (65.0%)






Systemic hypertension 18 (90%)
Hyperlipidaemia/hypercholesterolaemia 15 (75%)
Coronary artery disease 10 (50%)
Rheumatic fever 5 (25%)
Myocardial infarction 2 (10%)
Smoker (past or current) 3 (15%)
Cerebrovascular disease 1 (5%)
NYHA — New York Heart Association; SD — standard deviation
Table 2. Operative outcomes
Parameter Percentage (n) 





Dystrophic calcification 2 (10.0%)
Rheumatic 6 (30.0%)






Full sternotomy 15 (75.0%)
Upper hemi sternotomy 5 (25.0%)
Cardiopulmonary bypass time [min] 100.4 ± 22.3 (69–155)
Cross clamp time [min] 59.6 ± 10.3 (43–78)
Length of stay [days] 9.5 ± 3.7 (7–20)
SD — standard deviation
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nological and anti-degenerative tissue material [24]. However, 
a common problem with glutaraldehyde treatment of tissue 
that remains an area of development to date is the residual 
aldehydes, free acids, and Schiff bases that are by-products 
of the tissue fixation process. These functional groups serve as 
potential binding sites for calcium, phosphates, and immuno-
genic agents that contribute to the deterioration of the valve. 
Attempts to reduce bioburden by capping these functional 
groups with various agents (proteins, amino acids, or amines) 
have been proposed, but these agents are not permanent as 
they diffuse out of the tissue over time [25, 26]. 
Recently, a technique to remove unstable glutaraldehyde 
residuals through a combination of both thermal and chemical 
agents was developed. This tissue process, TFX, applied to bo-
vine pericardial valves has demonstrated excellent clinical safety 
and durability [27, 28]. To further enhance the TFX technology 
for prolonged valve durability, a novel anti-calcification technol-
ogy platform was created to irreversibly cap the aldehyde groups 
through reductive amination [17]. The technology platform, 
GLX, introduces the additional step of capping, reducing, and 
glycerolisation, thereby eliminating sites that would otherwise 
be exposed as potential binding sites for calcium, phosphate, 
and immunogenic agents [18]. In addition, the GLX process 
allows for non-liquid storage, inhibiting oxidation in of the tis-
sue and prolonging the lifetime of the tissue. When comparing 
the anti-calcification efficacy in a rabbit intramuscular implant 
study, the GLX processed pericardial tissue demonstrated a 93% 
reduction in calcium content compared to the TFX-processed 
pericardial tissue at 35 days [18]. 
These promising findings led to further investigation in 
the clinical setting, and this report demonstrates the one-year 
clinical outcomes of a bioprosthetic valve treated with the 
novel anti-calcification GLX technology platform. This initial 
clinical experience with a GLX-treated valve in the aortic 
position demonstrated excellent valve performance and 
safety. The study showed complete freedom from the primary 
endpoints. Additionally, significant improvement in NYHA 
class and in haemodynamic performance up to one year 
was observed. 
This initial clinical experience demonstrates safety, ef-
ficacy, and feasibility with an enhanced bioprosthetic valve 
for prolonged durability. With increased life expectancies, 
durable bioprosthetic options such as these are critical for 
both younger and elderly patients undergoing biopros-
thetic AVR [1, 29]. Additionally, options for younger patients 
(< 60 years), which represent a growing subset of the AVR 
candidate population, need further focus and development. 
As tissue valve durability has been increasing and the mean 
age of AVR patients has increased, the recommended age for 
AVR with bioprosthesis was recently lowered from patients 
aged 65 years or older to patients aged 60 years or older by the 
American Heart Association and the American College of Car-
diology [6]. This places further importance on valve durability 
research and development as the under-appreciated area 
of valvular heart disease represents a growing public-health 
concern affecting an increasingly wide span of patients. The 
novel anti-calcification technology platform described in 
this study shows promising initial clinical outcomes, and ad-
ditional enrolment and longer-term follow-up is ongoing to 
verify these results. 
Limitations of the study
The present study was a non-randomised, single-arm study. 
A concurrent control group was not studied in this clinical 
trial. Additional limitations include a small patient cohort and 
a follow-up period that extends only to one year. Long-term 
performance and complications need to be examined to test 
the durability of the valve for which the prosthesis was de-
signed. Much larger cohorts should be investigated with the 
use of this novel anti-calcification tissue processing technology.
CONCLUSIONS
This early clinical experience using an aortic bioprosthetic valve 
treated with a novel anti-calcification tissue processing tech-
Table 3. Haemodynamic performance
Valve size 
21 mm 23 mm 25 mm 27 mm
Effective orifice area [cm2] N: Mean ± SD
Baseline 8: 0.8 ± 0.3 9: 1.1 ± 0.7 2: 0.7 ± 0.1 1: 0.8 ± N/A
1 year 7: 1.7 ± 0.5 8: 1.7 ± 0.5 2: 2.1 ± 0.2 1: 2.0 ± N/A
P 0.0009 0.0630 0.0125 N/A
Mean gradient [mm Hg] N: Mean ± SD
Baseline 8: 54.8 ± 16.4 9: 49.9 ± 26.4 2: 73.7 ± 10.3 1: 61.1 ± N/A
1 year 7: 11.2 ± 3.0 8: 12.9 ± 3.0 2: 5.9 ± 2.7 1: 10.3 ± N/A
P 0.0001 0.0013 0.0121 N/A
‘N’ represent number of evaluable echocardiograms; SD — standard deviation; N/A — not applicable
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nology demonstrated excellent valve performance, durability, 
and safety at one year. Additional enrolment and longer-term 
follow-up is ongoing to verify these promising results.
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Wymiana zastawki aortalnej z nową 
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S t r e s z c z e n i e
Wstęp i cel: Główną przyczyną odległych uszkodzeń zastawki aortalnej są uszkodzenia strukturalne spowodowane zwapnie-
niem tkanek. Nowa platforma technologiczna antykalcyfikacji została opracowana w ten sposób, by nieodwracalnie blokować 
miejsca wiązania wapnia w zastawkach biologicznych.
Metody: Dwudziestu pacjentów z ciężką stenozą aortalną zostało poddanych operacji wymiany zastawki aortalnej z użyciem 
biologicznej zastawki aortalnej traktowanej nową technologią antykalcyfikacyjną. Średni wiek pacjentów i wskaźnik masy ciała 
wynosiły odpowiednio 73,7 ± 4,8 roku i 30,1 ± 5,8 kg/m2. Kobiety stanowiły 65% populacji, a 30% chorych było w klasie III 
lub IV wg NYHA. Nadciśnienie tętnicze stwierdzono u 90% pacjentów, hiperlipidemię — u 75%, cukrzycę — u 35%, niewydol-
ność nerek — u 25%, choroby płuc — u 10%, a zawał serca — u 10% osób. Pacjenci byli obserwowani do 1 roku od operacji. 
Zastawki oceniano hemodynamicznie na podstawie badania echokardiograficznego. Odnotowywano wszystkie powikłania.
Wyniki: Stwierdzono 1 wczesny zgon bez związku z zastawką w 5. dobie. Nie odnotowano żadnych innych powikłań do 
momentu wypisu ze szpitala. Kontrolę pooperacyjną po 3–6 miesiącach i po 1 roku przeprowadzono u 100% pacjentów. 
Po roku nie stwierdzono zgonu związanego z zastawką, uszkodzeń strukturalnych zastawki, przecieku okołozastawkowego 
(> 2+), zdarzeń zakrzepowo-zatorowych, poważnego krwawienia, zapalenia wsierdzia i nie wykonano reoperacji. Średnia 
efektywna powierzchnia ujścia zwiększyła się z 1,0 ± 0.5 cm2 na początku badania do 1,8 ± 0,5 cm2 po roku. Średni gradient 
zmniejszył się z 54,8 ± 21,2 mm Hg na początku badania do 11,3 ± 3,4 mm Hg po roku.
Wnioski: Wczesne doświadczenia kliniczne z zastosowaniem bioprotezy aortalnej traktowanej nową technologią antykalcyfi-
kacji i przetwarzania tkanek wskazują na jej doskonałą wydajność, trwałość i bezpieczeństwo. Nie zaobserwowano powikłań 
związanych z użytą zastawką. Konieczna jest długoterminowa obserwacja w celu zweryfikowania tych obiecujących wyników.
Słowa kluczowe: wymiana zastawki aortalnej, terapia antykalcyfikacyjna 
Kardiol Pol 2015; 73, 5: 317–322
